New research by scientists at the University of Washington, the Max Planck Institute for Dynamics and Self-Organization and the University of Cologne indicates that carefully designed cocktails of broadly neutralizing antibodies could help treat HIV while minimizing the risk of the virus evolving to “escape” treatment.
Using powerful tools and techniques developed in the field of structural biology, researchers at the University of Washington and Scripps Research have discovered new details about the human immunodeficiency virus, HIV. The findings bring into focus the basic architecture of the virus just above and below its surface and may help in the design and development of a vaccine that can protect against AIDS. These detailed findings include 3D views of the structure and position of the virus’ envelope “spike”…
The abundance of personal smartphones in southern African countries got University of Washington professor Sarah Gimbel thinking: What if these phones were used by front-line health workers — namely nurses — to collect and analyze data on patients living with HIV or AIDS to improve their care?
UW Health Sciences News Digest: Ebola outbreak, HIV persistence, back-to-school sleep routines
University of Washington bioengineers have discovered a potentially faster way to deliver a topical drug that protects women from contracting HIV. Their method spins the drug into silk-like fibers that quickly dissolve when in contact with moisture, releasing higher doses of the drug than possible with other materials.
News from the UW Health Sciences: Alzheimer’s impact on our aging population, hunger cues, trauma treatment study, avoiding burnout, training new neuroscientists, an AIDS-free generation
Funded by the NIH at $15 million over five years, the lab will be a national resource to evaluate candidate vaccines from studies around the country.
Holmes was honored for his groundbreaking work on sexually transmitted diseases, including HIV/AIDS, chlamydia, genital herpes, gonorrhea and human papilloma virus.
Electrically spun cloth with nanometer-sized fibers show promise as a cheap, versatile platform to simultaneously offer contraception and prevent HIV. New funding from the Bill & Melinda Gates Foundation will further test the system’s versatility and feasibility.
In evaluating whether to allow Truvada® to be prescribed for HIV prevention the FDA reviewed evidence from two studies. The largest was conducted by the UWs International Clinical Research Center.
The UW International Clinical Research Center played a key role in examining Truvada’s effectiveness for HIV prevention. The center’s director Connie Celum talks about the impact of the findings in a Q & A.
Dr. Shiu-Lok Hu and his colleagues are looking to generate protective antibodies targeting a part of the HIV virus that binds to immune cells. This segment is widely considered to be the Achilles heel of the virus
A UW-led study published in The Lancet Infectious Diseases shows a troubling link between hormonal contraception and HIV. The study is getting widespread press coverage because of the popularity of injectable birth control like Depo-Provera in parts of Africa hardest hit by the AIDS epidemic.